The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Organogenesis to File FDA License Application for ReNu Following Successful Meeting

Key Facts

1Organogenesis Holdings Inc. successfully completed a Type-B meeting with the FDA regarding its ReNu product.

2The FDA confirmed the initiation of a rolling Biologics License Application (BLA) for ReNu for knee osteoarthritis pain.

3The company plans to initiate the rolling BLA submission before the end of December 2025.

Create Free Account

Version History

3 additional sources confirmed this story

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA) regarding its ReNu product. The meeting confirmed the clinical development program's suitability for a rolling Biologics License Application (BLA) for treating knee osteoarthritis pain. The company plans to initiate the rolling BLA submission process before the end of December 2025. This regulatory milestone reduces clinical uncertainty and provides a clear pathway toward commercializing the regenerative medicine product. Investors typically view such positive regulatory progress favorably within the biotech sector. The announcement marks a significant step forward in the company's long-term growth strategy.